Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma

Frank V. Fossella; Rodger J. Winn; Paul Y. Holoye; Becky Hallinan; Martin N. Raber; Karen Hoelzer; James A. Young; Joseph Readling; Barbara Bowers; Waun Ki Hong

doi:10.1007/BF00944191

Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma

Frank V. Fossella, Rodger J. Winn, Paul Y. Holoye, Becky Hallinan, Martin N. Raber, Karen Hoelzer, James A. Young, Joseph Readling, Barbara Bowers, Waun Ki Hong

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

We treated 34 chemotherapy-naive patients with stage IIIb or IV non-small cell lung cancer with trimetrexate 150-200 mg/m² intravenously over 30 minutes every two weeks. Six of 31 evaluable patients (19%) achieved a partial response. The major toxic effects from this regimen were myelosuppression, nausea/vomiting, and skin rash. We conclude that this well-tolerated schedule of trimetrexate has significant activity as a single agent against non-small cell lung cancer.

Original language	English (US)
Pages (from-to)	331-335
Number of pages	5
Journal	Investigational New Drugs
Volume	10
Issue number	4
DOIs	https://doi.org/10.1007/BF00944191
State	Published - Nov 1992

Keywords

non-small cell lung cancer
phase II trial
trimetrexate

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00944191

Cite this

@article{063ec41bb94541d1905e9b319737229f,

title = "Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma",

abstract = "We treated 34 chemotherapy-naive patients with stage IIIb or IV non-small cell lung cancer with trimetrexate 150-200 mg/m2 intravenously over 30 minutes every two weeks. Six of 31 evaluable patients (19%) achieved a partial response. The major toxic effects from this regimen were myelosuppression, nausea/vomiting, and skin rash. We conclude that this well-tolerated schedule of trimetrexate has significant activity as a single agent against non-small cell lung cancer.",

keywords = "non-small cell lung cancer, phase II trial, trimetrexate",

author = "Fossella, {Frank V.} and Winn, {Rodger J.} and Holoye, {Paul Y.} and Becky Hallinan and Raber, {Martin N.} and Karen Hoelzer and Young, {James A.} and Joseph Readling and Barbara Bowers and Hong, {Waun Ki}",

year = "1992",

month = nov,

doi = "10.1007/BF00944191",

language = "English (US)",

volume = "10",

pages = "331--335",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "4",

}

TY - JOUR

T1 - Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma

AU - Fossella, Frank V.

AU - Winn, Rodger J.

AU - Holoye, Paul Y.

AU - Hallinan, Becky

AU - Raber, Martin N.

AU - Hoelzer, Karen

AU - Young, James A.

AU - Readling, Joseph

AU - Bowers, Barbara

AU - Hong, Waun Ki

PY - 1992/11

Y1 - 1992/11

N2 - We treated 34 chemotherapy-naive patients with stage IIIb or IV non-small cell lung cancer with trimetrexate 150-200 mg/m2 intravenously over 30 minutes every two weeks. Six of 31 evaluable patients (19%) achieved a partial response. The major toxic effects from this regimen were myelosuppression, nausea/vomiting, and skin rash. We conclude that this well-tolerated schedule of trimetrexate has significant activity as a single agent against non-small cell lung cancer.

AB - We treated 34 chemotherapy-naive patients with stage IIIb or IV non-small cell lung cancer with trimetrexate 150-200 mg/m2 intravenously over 30 minutes every two weeks. Six of 31 evaluable patients (19%) achieved a partial response. The major toxic effects from this regimen were myelosuppression, nausea/vomiting, and skin rash. We conclude that this well-tolerated schedule of trimetrexate has significant activity as a single agent against non-small cell lung cancer.

KW - non-small cell lung cancer

KW - phase II trial

KW - trimetrexate

UR - http://www.scopus.com/inward/record.url?scp=0027055768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027055768&partnerID=8YFLogxK

U2 - 10.1007/BF00944191

DO - 10.1007/BF00944191

M3 - Article

C2 - 1336771

AN - SCOPUS:0027055768

SN - 0167-6997

VL - 10

SP - 331

EP - 335

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 4

ER -

Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this